Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Sources say Hyundai has said that a final decision has not yet been made regarding the Russian plant.
2025-12-29
Sources say Hyundai has said that a final decision has not yet been made regarding the Russian plant.
Back
Other News
2025-12-29
Goldwind Technology hit its daily limit today, with a turnover of 4.67 billion yuan and a turnover rate of 6.57%. Post-market data shows that the Shenzhen-Hong Kong Stock Connect bought 178 million yuan and sold 99.2914 million yuan, while four insti
Goldwind Technology hit its daily limit today, with a turnover of 4.67 billion yuan and a turnover rate of 6.57%. Post-market data shows that the Shenzhen-Hong Kong Stock Connect bought 178 million yuan and sold 99.2914 million yuan, while four institutional investors had a net sale of 374 million yuan.
2025-12-29
[CR Double-Crane: Hydroxycobalamin Injection Receives Clinical Trial Approval] CR Double-Crane announced that it recently received the "Drug Clinical Trial Approval Notice" for its hydroxycobalamin injection issued by the National Medical Products Ad
[CR Double-Crane: Hydroxycobalamin Injection Receives Clinical Trial Approval] CR Double-Crane announced that it recently received the "Drug Clinical Trial Approval Notice" for its hydroxycobalamin injection issued by the National Medical Products Administration. The notice indicates that hydroxycobalamin injection is suitable for the treatment of metabolic disorders in children with methylmalonic acidemia with or without homocysteineemia. The company received the acceptance notice on October 22, 2025, and the "Drug Clinical Trial Approval Notice" on December 25, 2025. As of the date of this announcement, the company's cumulative R&D investment in this drug is RMB 13,058,100 (unaudited).
Chat with us
, powered by
LiveChat